The US National Institutes of Health's US$240-million epigenomics investment could improve the study of disease biology, the identification of new drug targets, the validation of animal models and more.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. The Roadmap Epigenomics Project opens new drug development avenues. Nat Rev Drug Discov 14, 223–225 (2015). https://doi.org/10.1038/nrd4582
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4582